Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial

Phase II Readout Expected Later This Year

Executive Summary

PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery

You may also be interested in...



Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut

Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.

The BioPharma Shares Rising On Omicron Hopes And Fears

Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.

Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio

AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel